Microbial biopharmaceuticals Market: By Microbe Type, By End product, By Application and Region Forecast 2020-2031

Microbial biopharmaceuticals Market Size, Share, Growth, Trends, and Global Industry Analysis: By Microbe Type (Bacteria, Fungal & Yeast, Virus), By End product (Vaccines, Hormones, Antibody Derived Proteins, PEGylated Products, BL-2 Products), By Application (Metabolic Disorders, Hormonal Disorders, Homological Disorders, Oncological Disorders) and Region Forecast 2020-2031

Microbial Biopharmaceuticals Market size was valued at US$ 353.3 billion in 2024 and is expected to reach US$ 922.7 billion by 2031, growing at a significant CAGR of 14.7% from 2025-2031. The market Increase in the geriatric population and changes in lifestyles are increasing the demand for biopharmaceuticals. An increase in research facilities and more approved biopharmaceutical products in the market are also key factors affecting the market. Frequent cases of side effects and incompatibilities in cases of mammalian or plant-obtained biopharmaceutical products cause the rise in demand for microbial products as they do not possess any side effects. They can be manufactured easily at low cost and are more stable in atmospheric and biological conditions.

Microbes have been used to make bread, wine, vinegar, and other common items for millennia, with no one knowing the scientific basis. Nonmicrobial goods such as insulin, interferon, human growth hormone, and viral vaccinations are now commercially produced using genetically altered organisms. Microbes are also employed to produce energy (biodiesel and bioethanol), as well as to clean up contaminants like sewage and oil spills. Microorganisms contribute to increased agricultural production as active ingredients in biofertilizers and biopesticides, and microbes are the foundation of cost-effective mining and metallurgical technologies. The global market is surging owing to frequent acquisitions and launches by the market players.

Key Development:

In 2013, Sanofi a French pharmaceutical company announced that a strain of baker's yeast capable of producing malaria drugs on an industrial scale had been successfully engineered by their researchers and it is commercially available now.

Microbial Biopharmaceuticals Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

14.7%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Microbial Biopharmaceuticals Market Dynamics

Microbial biopharmaceuticals are simply defined as biopharmaceutical products which are extracted from microbial species by using recombinant DNA technology. These products have various benefits when compared to other biopharmaceutical products such as easy manufacture and extraction, low of cost, more stability, high potency, no or very less side effects and high therapeutic nature etc. thus, the market for these microbial biopharmaceuticals are showing significant growth.

Microbial Biopharmaceuticals Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 353.3 billion

Market Size in 2031

US$ 922.7 billion

Market CAGR

14.7%

By Microbe Type

  • Bacteria
  • Fungal & Yeast
  • Virus
  • Other microbes

By End Product

  • Vaccines
  • Hormones
  • Antibody derived proteins
  • PEGylated products
  • BL-2 Products

By Application

  • Metabolic disorders
  • Hormonal disorders
  • Hematological disorders
  • Oncological disorders
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The rheumatoid arthritis treatment market report provides granular level information about the market size, regional market share, historic market (2020 to 2024), and forecast (2025 to 2031)
  • The report covers in-detail insights into the competitor's overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and startup details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

The microbial biopharmaceuticals market size was valued at US$ 353.3 billion in 2024 and is expected to reach US$ 922.7 billion by 2031, growing at a significant CAGR of 14.7% from 2025-2031.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The market key players are AbbVie Inc. (Abbott), A-Bio Pharma Pte Ltd., ABL, Inc., Affinity Life Sciences, Inc., Ajinomoto Aminoscience, LLC, Alexion Pharmaceuticals, Alliance Medical Products, Inc.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

Key Market Players

  • AbbVie Inc. (Abbott)
  • A-Bio Pharma Pte Ltd.
  • ABL, Inc.
  • Affinity Life Sciences, Inc.
  • Ajinomoto Aminoscience, LLC
  • Alexion Pharmaceuticals
  • Alliance Medical Products, Inc.
  • Alpha Biologics
  • Baxter BioPharma Solutions/Baxter Bioscience
  • Biogen Idec
  • BIOMEVA GmbH
  • Biotecnol
  • Boehringer Ingelheim GmbH
  • Boston Mountain Biotech
  • Celonic
  • Crucell /Johnson & Johnson
  • FUJIFILM Diosynth Biotechnologies
  • Genentech/Roche
  • GlaxoSmithKline
  • Glycobia
  • Lonza AG
  • Merck & Co. Inc
  • Novartis
  • Pfizer
  • ProBioGen AG
  • Regeneron Pharmaceuticals
  • Rentschler Biotechnologie
  • Royal DSM
  • Sandoz
  • Sanofi Pasteur

Related Industry Reports